Harmony Biosciences Holdings

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S. Aronin on July 25, 2017 and is headquartered in Plymouth Meeting, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Harmony Biosciences excels in Q4, eyes growth in new markets

Harmony Biosciences delivered strong financial results, emphasizing growth strategies and confidence in WAKIX's revenue potential. The company is well-positioned with a focus on new prescribers, lifecycle management, and potential business development opportunities.

Harmony Biosciences excels in Q1, eyes expansion and shareholder value

Harmony Biosciences' Q1 2023 showcased strong financial performance, significant patient growth on WAKIX, and strategic plans for portfolio expansion.
The company's commercial model evolution and confidence in WAKIX's growth potential position it well for future opportunities.
Addressing challenges like patient attrition rates and regulatory concerns while exploring new business development avenues highlight Harmony's proactive approach.
With a focus on maximizing shareholder value and sustaining growth post-WAKIX, Harmony Biosciences remains poised for continued success.

Harmony Biosciences excels in Q2, eyes growth amid challenges

Harmony Biosciences delivered a strong Q2 performance, showcasing growth in net sales and patient numbers for WAKIX. The company's financial strength, strategic capital deployment, and focus on clinical development programs position it well for future growth. While facing challenges like patent disputes and market dynamics, Harmony Biosciences remains confident in its business fundamentals and growth potential.

Harmony Biosciences Achieves Record Revenue in Q3 2023

Harmony Biosciences delivered a stellar performance in Q3 2023, marked by record revenue, strong profitability, and strategic acquisitions, positioning the company for future growth.
While facing challenges in patent litigation and regulatory approvals, the company's focus on innovation, commercial excellence, and financial strength underpin its resilience.
With a clear market opportunity in narcolepsy, ongoing pipeline advancements, and a commitment to shareholder value, Harmony Biosciences remains well-positioned for long-term success.

Harmony Biosciences reports robust earnings, eyes strategic growth in 2024

Harmony Biosciences' strong financial performance, strategic acquisitions, and clinical advancements position the company for continued growth and market success.
Balancing revenue growth, pricing strategies, and clinical developments will be key focus areas for the company in navigating market challenges and opportunities.
With a focus on innovation, regulatory relationships, and financial prudence, Harmony Biosciences aims to drive sustainable growth and shareholder value in 2024.
The company's proactive approach to business development, share repurchases, and revenue guidance reflects a strategic and forward-thinking mindset for future success.

Harmony Biosciences excels in Q1, poised for long-term growth

Harmony Biosciences delivered strong financial performance in Q1, driven by WAKIX's growth and strategic acquisitions, positioning the company for continued success.
Despite operational challenges and market competition, the company's focus on innovation, rare disease treatments, and CNS franchises presents significant growth opportunities.
With a robust financial position, disciplined capital deployment, and a promising pipeline, Harmony Biosciences is poised for long-term value creation and revenue growth.
FDA recognition of unmet medical needs, positive clinical developments, and strong IP protection underscore the company's potential for market leadership and patient impact.

Harmony Biosciences reports robust Q2 performance and growth opportunities

Harmony Biosciences delivered a strong Q2 performance with revenue growth, FDA approvals, and pipeline advancements. The company's financial strength, upheld patents, and strategic growth focus position it well for future success despite some challenges.

Harmony Biosciences excels in Q3, eyes growth amid legal challenges

Harmony Biosciences demonstrated strong financial performance and pipeline progress in Q3 2024, positioning itself for continued growth.
While facing IP litigation and challenges in rare orphan categories, the company's focus on innovation and market positioning presents opportunities for future success.
Maintaining financial strength, pursuing pipeline advancements, and navigating legal hurdles will be key for Harmony Biosciences' sustained growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES--(BUSINESS WIRE)---- $HRMY #HRMY--The Schall Law Firm Announces it is Investigating Claims Against Harmony Biosciences Holdings, Inc.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Harmony Biosciences Holdings, Inc. and Encourages Investors with Losses to Contact the Firm

PLYMOUTH MEETING, Pa. , March 29, 2023 /PRNewswire/ --  Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced an accelerated timeline for completing its Phase 3 INTUNE study evaluating the safety and efficacy of pitolisant in adult patients with idiopathic hypersomnia (IH).

HARMONY BIOSCIENCES ANNOUNCES ACCELERATED TIMELINE FOR PHASE 3 INTUNE STUDY IN IDIOPATHIC HYPERSOMNIA

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (NASDAQ: HRMY) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate.

The Law Offices of Frank R. Cruz Announces Investigation of Harmony Biosciences Holdings, Inc. (HRMY) on Behalf of Investors

OAKLAND, Calif.--(BUSINESS WIRE)---- $HRMY #HRMY--Gibbs Law Group is investigating potential claims on behalf of Harmony Biosciences (HRMY) investors.

Lost Money in Harmony Biosciences Holdings Inc.?

Harmony has only one approved therapy, Wakix, to treat excessive daytime sleepiness. The drug was responsible for all of the company's revenue in 2022.

Why Shares of Harmony Bioscience Are Slumping Tuesday

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Harmony Biosciences Holdings, Inc. and Encourages Investors with Losses to Contact the Firm

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) resulting from allegations that Harmony Biosciences may have issued materially misleading business information to the investing public.

EQUITY ALERT: Rosen Law Firm Encourages Harmony Biosciences Holdings, Inc. Investors with Losses to Inquire About Securities Class Action Investigation – HRMY

Shares of Harmony Biosciences (NASDAQ: HRMY ) stock are plunging lower by about 25% following a short report from Scorpion Capital. The activist short seller spent four months researching the report, which included interviews with former executives and employees, physicians and senior scientists.

HRMY Stock Alert: Scorpion Short Report Sends Harmony Plunging

Biogen

Incyte

Inspire Medical Systems Inc

Eli Lilly

McKesson

Merck

Stock market investors have been on a rollercoaster ride over the past year. The Federal Reserve continues to be hawkish in controlling inflation.

7 Healthcare Stocks to Buy for Long-Term Growth and Stability

Today, we circle back on a biopharma name called Harmony Biosciences Holdings. The company recently posted solid fourth quarter results, and the stock seems undervalued after an approximate 30% decline from recent highs.

Harmony Biosciences: Why I Am Adding More Shares

The annual funding programs support patient-centric initiatives within rare neurological disease and sleep disorder communities Applications for Patients at the Heart and Progress at the Heart open today, Tuesday, February 28, timed to "Rare Disease Day" PLYMOUTH MEETING, Pa. , Feb. 28, 2023 /PRNewswire/ -- Community and nonprofit organizations throughout the country that are working to support patient-centric initiatives within rare neurological diseases and sleep disorders will have the opportunity to receive funding to support innovative initiatives, thanks to the continuation of Harmony Biosciences' Patients at the Heart and Progress at the Heart programs.

HARMONY BIOSCIENCES CONTINUES COMMUNITY COMMITMENT IN 2023 WITH PATIENTS AT THE HEART AND PROGRESS AT THE HEART NONPROFIT FUNDING PROGRAMS

Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 87.04% and 0.46%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings and Revenues Beat Estimates

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY ) Q4 2022 Earnings Conference Call February 21, 2023 8:30 AM ET Company Participants Luis Sanay - Head-Investor Relations Jeffrey Dierks - Chief Commercial Officer Jeffrey Dayno - Interm CEO & Chief Medical Officer Sandip Kapadia - Chief Financial Officer Conference Call Participants Francois Brisebois - Oppenheimer David Amsellem - Piper Sandler Chris Howerton - Jefferies Charles Duncan - Cantor Fitzgerald Corinne Jenkins - Goldman Sachs Ami Fadia - Needham Graig Suvannavejh - Mizuho Securities Danielle Brill - Raymond James Operator Good morning everyone. My name is Todd and I will be your conference operator today.

Harmony Biosciences Holdings, Inc. (HRMY) Q4 2022 Earnings Call Transcript

Harmony Biosciences beat quarterly expectations Tuesday, leading the biotech stock to surge despite a barrage of commercial concerns. The post Harmony Biosciences, The No.

Harmony Biosciences, The No. 3 Biotech, Just Topped Forecasts; But Concerns Persist

WAKIX® (pitolisant) Net Revenue Increased ~41% Year-over-Year to $128.3 Million for Fourth Quarter 2022; ~43% to $437.9 Million for Full Year 2022

Harmony Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

Recognition reinforces strong company culture and employee experience PLYMOUTH MEETING, Pa. , Feb. 17, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for people with rare neurological diseases, today announced the company has earned the Great Place to Work® recognition for the fifth year in a row.

HARMONY BIOSCIENCES CERTIFIED AS A GREAT PLACE TO WORK® FOR FIFTH CONSECUTIVE YEAR

Chimerix

Genfit - ADR

iTeos Therapeutics, Inc.

Regeneron Pharmaceuticals

Selecta Biosciences

Vertex Pharmaceuticals

While unpredictable compared to other sectors due to the ebb and flow of clinical trials, the best biotech stocks to buy offer investors incredible upside opportunities. Better yet, the volatility largely centers on developments of the industry itself rather than the broader economy.

The 7 Best Biotech Stocks to Buy for February 2023

PLYMOUTH MEETING, Pa. , Feb. 7, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it will report fourth quarter and full year 2022 financial results on Tuesday, February 21, 2023, before the open of the U.S. financial markets.

HARMONY BIOSCIENCES TO REPORT FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS ON FEBRUARY 21, 2023

Novo Nordisk

UnitedHealth Group

Vir Biotechnology

Healthcare stocks performed well in 2022, driven by a number of factors. One of the main drivers was the ongoing COVID-19 pandemic, which continued to boost demand for healthcare products and services.

7 Healthcare Stocks That Will Be Big Winners in 2023

Catalyst Pharmaceuticals

Catalyst Pharmaceuticals and Harmony Bioscience each have a single product in their respective pipelines, and both show incredible promise.

2 Biotechs Making Waves With A Single Product in their Pipeline

Harmony Biosciences Holdings, Inc. (HRMY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in Harmony Biosciences Holdings, Inc. (HRMY): Can Its 5.1% Jump Turn into More Strength?

PLYMOUTH MEETING, Pa. , Jan. 6, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that John C.

HARMONY BIOSCIENCES APPOINTS JEFFREY M. DAYNO, MD AS INTERIM CEO AND EXPANDS ROLE OF JEFF ARONIN TO EXECUTIVE CHAIRMAN

ProFrac Holding Corp

Despite a struggling IPO market in 2022, Harmony Biosciences and ProFrac are holding up well in the ongoing stock market correction. The post IPO Stock Leaders Harmony, ProFrac Outperform Despite Tough 2022 Market appeared first on Investor's Business Daily.

IPO Stock Leaders Harmony, ProFrac Outperform Despite Tough 2022 Market

PLYMOUTH MEETING, Pa. , Dec. 22, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that President and CEO, John C.

HARMONY BIOSCIENCES TO PRESENT AT THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Harmony has done very well in the few months since I last covered it. I was overly cautious then and did not buy what I see could have been a great investment.

News for Harmony Biosciences Holdings Stock (HRMY)